Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 263

1.

Maternal obesity leads to long-term altered levels of plasma ceramides in the offspring as revealed by a longitudinal lipidomic study in children.

León-Aguilar LF, Croyal M, Ferchaud-Roucher V, Huang F, Marchat LA, Barraza-Villarreal A, Romieu I, Ramakrishnan U, Krempf M, Ouguerram K, Mercado-Camargo R, Bolaños-Jiménez F.

Int J Obes (Lond). 2018 Dec 19. doi: 10.1038/s41366-018-0291-y. [Epub ahead of print]

PMID:
30568270
2.

Plasma lipidomic analysis reveals strong similarities between lipid fingerprints in human, hamster and mouse compared to other animal species.

Kaabia Z, Poirier J, Moughaizel M, Aguesse A, Billon-Crossouard S, Fall F, Durand M, Dagher E, Krempf M, Croyal M.

Sci Rep. 2018 Oct 26;8(1):15893. doi: 10.1038/s41598-018-34329-3.

3.

In vivo evidence for transintestinal cholesterol efflux in patients with complete common bile duct obstruction.

Moreau F, Blanchard C, Perret C, Flet L, Douane F, Frampas E, Mirallie E, Croyal M, Aguesse A, Krempf M, Prieur X, Pichelin M, Cariou B, Le May C.

J Clin Lipidol. 2019 Jan - Feb;13(1):213-217.e1. doi: 10.1016/j.jacl.2018.09.010. Epub 2018 Sep 21.

PMID:
30342919
4.

High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.

Béliard S, Boccara F, Cariou B, Carrié A, Collet X, Farnier M, Ferrières J, Krempf M, Peretti N, Rabès JP, Varret M, Vimont A, Charrière S, Bruckert E; French FH Registry group.

Atherosclerosis. 2018 Oct;277:334-340. doi: 10.1016/j.atherosclerosis.2018.08.010.

PMID:
30270068
5.

[Familial hypercholesterolemia: An under-diagnosed and under-treated disease. Survey of 495 physicians].

Béliard S, Rabès JP, Cariou B, Farnier M, Krempf M, Ferrières J, Danchin N, Bruckert E.

Presse Med. 2018 Sep;47(9):e159-e167. doi: 10.1016/j.lpm.2018.01.025. Epub 2018 Jul 27. French.

PMID:
30060905
6.

New rare genetic variants of LMF1 gene identified in severe hypertriglyceridemia.

Serveaux Dancer M, Di Filippo M, Marmontel O, Valéro R, Piombo Rivarola MDC, Peretti N, Caussy C, Krempf M, Vergès B, Mahl M, Marçais C, Moulin P, Charrière S.

J Clin Lipidol. 2018 Sep - Oct;12(5):1244-1252. doi: 10.1016/j.jacl.2018.06.018. Epub 2018 Jul 7.

PMID:
30037590
7.

Consequences of blunting the mevalonate pathway in cancer identified by a pluri-omics approach.

Goulitquer S, Croyal M, Lalande J, Royer AL, Guitton Y, Arzur D, Durand S, Le Jossic-Corcos C, Bouchereau A, Potin P, Akoka S, Antignac JP, Krempf M, Ferchaud-Roucher V, Giraudeau P, Corcos L.

Cell Death Dis. 2018 Jul 3;9(7):745. doi: 10.1038/s41419-018-0761-0.

8.

Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis.

Adiels M, Chapman MJ, Robillard P, Krempf M, Laville M, Borén J; Niacin Study Group.

J Clin Lipidol. 2018 May - Jun;12(3):810-821.e1. doi: 10.1016/j.jacl.2018.03.083. Epub 2018 Mar 29.

9.

PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate.

Croyal M, Tran TT, Blanchard RH, Le Bail JC, Villard EF, Poirier B, Aguesse A, Billon-Crossouard S, Ramin-Mangata S, Blanchard V, Nativel B, Chemello K, Khantalin I, Thedrez A, Janiak P, Krempf M, Boixel C, Lambert G, Guillot E.

Clin Sci (Lond). 2018 May 31;132(10):1075-1083. doi: 10.1042/CS20180040. Print 2018 May 31.

PMID:
29724769
10.

Kinetics of plasma apolipoprotein E isoforms by LC-MS/MS: a pilot study.

Blanchard V, Ramin-Mangata S, Billon-Crossouard S, Aguesse A, Durand M, Chemello K, Nativel B, Flet L, Chétiveaux M, Jacobi D, Bard JM, Ouguerram K, Lambert G, Krempf M, Croyal M.

J Lipid Res. 2018 May;59(5):892-900. doi: 10.1194/jlr.P083576. Epub 2018 Mar 14.

11.

Stable Isotope Kinetic Study of ApoM (Apolipoprotein M).

Croyal M, Billon-Crossouard S, Goulitquer S, Aguesse A, León L, Fall F, Chétiveaux M, Moyon T, Blanchard V, Ouguerram K, Lambert G, Nobécourt E, Krempf M.

Arterioscler Thromb Vasc Biol. 2018 Jan;38(1):255-261. doi: 10.1161/ATVBAHA.117.310208. Epub 2017 Nov 16.

PMID:
29146748
12.

Roux-en-Y gastric bypass reduces plasma cholesterol in diet-induced obese mice by affecting trans-intestinal cholesterol excretion and intestinal cholesterol absorption.

Blanchard C, Moreau F, Ayer A, Toque L, Garçon D, Arnaud L, Borel F, Aguesse A, Croyal M, Krempf M, Prieur X, Neunlist M, Cariou B, Le May C.

Int J Obes (Lond). 2018 Mar;42(3):552-560. doi: 10.1038/ijo.2017.232. Epub 2017 Sep 28.

PMID:
29135972
13.

Perinatal Hypercholesterolemia Exacerbates Atherosclerosis Lesions in Offspring by Altering Metabolism of Trimethylamine-N-Oxide and Bile Acids.

Trenteseaux C, Gaston AT, Aguesse A, Poupeau G, de Coppet P, Andriantsitohaina R, Laschet J, Amarger V, Krempf M, Nobecourt-Dupuy E, Ouguerram K.

Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):2053-2063. doi: 10.1161/ATVBAHA.117.309923. Epub 2017 Sep 21.

PMID:
28935756
14.

Plasma Lipidome Analysis by Liquid Chromatography-High Resolution Mass Spectrometry and Ion Mobility of Hypertriglyceridemic Patients on Extended-Release Nicotinic Acid: a Pilot Study.

Ferchaud-Roucher V, Croyal M, Moyon T, Zair Y, Krempf M, Ouguerram K.

Cardiovasc Drugs Ther. 2017 Jun;31(3):269-279. doi: 10.1007/s10557-017-6737-y.

PMID:
28752209
15.

[Screening for disturbed eating behavior in adolescents with type 1 diabetes].

Feigel-Guiller B, Baron S, Rocher B, Krempf M.

Arch Pediatr. 2017 Jul;24(7):695-696. doi: 10.1016/j.arcped.2017.04.008. Epub 2017 Jun 2. French. No abstract available.

PMID:
28583779
16.

[Familial hypercholesterolemia: A largely underestimated cardiovascular risk].

Ferrières J, Bruckert É, Béliard S, Rabès JP, Farnier M, Krempf M, Cariou B, Danchin N.

Ann Cardiol Angeiol (Paris). 2018 Feb;67(1):1-8. doi: 10.1016/j.ancard.2017.04.015. Epub 2017 May 31. French.

PMID:
28576280
17.

Fenofibrate decreases plasma ceramide in type 2 diabetes patients: A novel marker of CVD?

Croyal M, Kaabia Z, León L, Ramin-Mangata S, Baty T, Fall F, Billon-Crossouard S, Aguesse A, Hollstein T, Sullivan DR, Nobecourt E, Lambert G, Krempf M.

Diabetes Metab. 2018 Mar;44(2):143-149. doi: 10.1016/j.diabet.2017.04.003. Epub 2017 May 9.

PMID:
28499696
18.

Model Free iPID Control for Glycemia Regulation of Type-1 Diabetes.

MohammadRidha T, Ait-Ahmed M, Chaillous L, Krempf M, Guilhem I, Poirier JY, Moog CH.

IEEE Trans Biomed Eng. 2018 Jan;65(1):199-206. doi: 10.1109/TBME.2017.2698036. Epub 2017 Apr 25.

PMID:
28459682
19.

Severe decrease in high-density lipoprotein cholesterol with the combination of fibrates and ezetimibe: A case series.

Nobecourt E, Cariou B, Lambert G, Krempf M.

J Clin Lipidol. 2017 Jan - Feb;11(1):289-293. doi: 10.1016/j.jacl.2016.10.012. Epub 2016 Nov 2.

PMID:
28391898
20.

Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials.

Catapano AL, Lee LV, Louie MJ, Thompson D, Bergeron J, Krempf M.

Sci Rep. 2017 Apr 4;7:45788. doi: 10.1038/srep45788.

21.

Antibiotic exposure and bacterial resistance in human and veterinary medicine: a problem-based learning topic for Master's students.

Eveillard M, Pouliquen H, Ruvoen N, Couvreur S, Krempf M, Magras C, Lepelletier D.

FEMS Microbiol Lett. 2017 Mar 1;364(6). doi: 10.1093/femsle/fnx015.

PMID:
28119372
22.

The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies.

Lambert G, Thedrez A, Croyal M, Ramin-Mangata S, Couret D, Diotel N, Nobécourt-Dupuy E, Krempf M, LeBail JC, Poirier B, Blankenstein J, Villard EF, Guillot E.

Clin Sci (Lond). 2017 Feb 1;131(4):261-268. doi: 10.1042/CS20160403. Review.

PMID:
28108631
23.

Plasma PCSK9 measurement by liquid chromatography-Tandem mass spectrometry and comparison with conventional ELISA.

Croyal M, Fall F, Krempf M, Thédrez A, Ouguerram K, Ferchaud-Roucher V, Aguesse A, Billon-Crossouard S, Mata P, Alonso R, Lambert G, Nobécourt E.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Feb 15;1044-1045:24-29. doi: 10.1016/j.jchromb.2016.12.040. Epub 2016 Dec 31.

PMID:
28064066
24.

A consensus statement on lipid management after acute coronary syndrome.

Schiele F, Farnier M, Krempf M, Bruckert E, Ferrières J; French Group.

Eur Heart J Acute Cardiovasc Care. 2018 Sep;7(6):532-543. doi: 10.1177/2048872616679791. Epub 2016 Nov 17. Review.

PMID:
27856518
25.

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab.

Villard EF, Thedrez A, Blankenstein J, Croyal M, Tran TT, Poirier B, Le Bail JC, Illiano S, Nobécourt E, Krempf M, Blom DJ, Marais AD, Janiak P, Muslin AJ, Guillot E, Lambert G.

JACC Basic Transl Sci. 2016 Oct;1(6):419-427. doi: 10.1016/j.jacbts.2016.06.006.

26.

[Management of dyslipidemia in adult].

Béliard S, Bonnet F, Bouhanick B, Charrière S, Cariou B, Durlach V, Moulin P, Valéro R, Vergès B, Boccara F, Farnier M, Feve B, Gourdy P, Guerci B, Krempf M, Moulin P.

Rev Prat. 2016 Sep;66(7):727-41. French. No abstract available.

PMID:
30512287
27.

IRES-dependent translation of the long non coding RNA meloe in melanoma cells produces the most immunogenic MELOE antigens.

Charpentier M, Croyal M, Carbonnelle D, Fortun A, Florenceau L, Rabu C, Krempf M, Labarrière N, Lang F.

Oncotarget. 2016 Sep 13;7(37):59704-59713. doi: 10.18632/oncotarget.10923.

28.

Identification of novel APOB mutations by targeted next-generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia.

Rimbert A, Pichelin M, Lecointe S, Marrec M, Le Scouarnec S, Barrak E, Croyal M, Krempf M, Le Marec H, Redon R, Schott JJ, Magré J, Cariou B.

Atherosclerosis. 2016 Jul;250:52-6. doi: 10.1016/j.atherosclerosis.2016.04.010. Epub 2016 Apr 11.

29.

Plasma ceramide, a real-time predictive marker of pulmonary and hepatic metastases response to stereotactic body radiation therapy combined with irinotecan.

Dubois N, Rio E, Ripoche N, Ferchaud-Roucher V, Gaugler MH, Campion L, Krempf M, Carrie C, Mahé M, Mirabel X, Paris F.

Radiother Oncol. 2016 May;119(2):229-35. doi: 10.1016/j.radonc.2016.03.014. Epub 2016 Apr 21.

30.

Integration of microbiology and infectious disease teaching courses in an interdisciplinary training programme (Master level) centred on the 'One world, one health' WHO concept.

Eveillard M, Ruvoen N, Lepelletier D, Fradet S, Couvreur S, Krempf M, Magras C.

FEMS Microbiol Lett. 2016 May;363(9). pii: fnw068. doi: 10.1093/femsle/fnw068. Epub 2016 Mar 23.

PMID:
27010013
31.

Comparison of gas chromatography-mass spectrometry and gas chromatography-combustion-isotope ratio mass spectrometry analysis for in vivo estimates of metabolic fluxes.

Croyal M, Bourgeois R, Ouguerram K, Billon-Crossouard S, Aguesse A, Nguyen P, Krempf M, Ferchaud-Roucher V, Nobécourt E.

Anal Biochem. 2016 May 1;500:63-5. doi: 10.1016/j.ab.2016.02.005. Epub 2016 Feb 17.

PMID:
26898306
32.

Multiplexed peptide analysis for kinetic measurements of major human apolipoproteins by LC/MS/MS.

Croyal M, Fall F, Ferchaud-Roucher V, Chétiveaux M, Zaïr Y, Ouguerram K, Krempf M, Nobécourt E.

J Lipid Res. 2016 Mar;57(3):509-15. doi: 10.1194/jlr.D064618. Epub 2016 Jan 15.

33.

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody.

Hopkins PN, Defesche J, Fouchier SW, Bruckert E, Luc G, Cariou B, Sjouke B, Leren TP, Harada-Shiba M, Mabuchi H, Rabès JP, Carrié A, van Heyningen C, Carreau V, Farnier M, Teoh YP, Bourbon M, Kawashiri MA, Nohara A, Soran H, Marais AD, Tada H, Abifadel M, Boileau C, Chanu B, Katsuda S, Kishimoto I, Lambert G, Makino H, Miyamoto Y, Pichelin M, Yagi K, Yamagishi M, Zair Y, Mellis S, Yancopoulos GD, Stahl N, Mendoza J, Du Y, Hamon S, Krempf M, Swergold GD.

Circ Cardiovasc Genet. 2015 Dec;8(6):823-31. doi: 10.1161/CIRCGENETICS.115.001129. Epub 2015 Sep 15.

34.

Nicotinic Acid Accelerates HDL Cholesteryl Ester Turnover in Obese Insulin-Resistant Dogs.

Le Bloc'h J, Leray V, Nazih H, Gauthier O, Serisier S, Magot T, Krempf M, Nguyen P, Ouguerram K.

PLoS One. 2015 Sep 14;10(9):e0136934. doi: 10.1371/journal.pone.0136934. eCollection 2015.

35.

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.

Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, Blom D, Civeira F, Krempf M, Lorenzato C, Zhao J, Pordy R, Baccara-Dinet MT, Gipe DA, Geiger MJ, Farnier M.

Eur Heart J. 2015 Nov 14;36(43):2996-3003. doi: 10.1093/eurheartj/ehv370. Epub 2015 Sep 1.

36.

Cardiovascular risk in relation to body mass index and use of evidence-based preventive medications in patients with or at risk of atherothrombosis.

Hansel B, Roussel R, Elbez Y, Marre M, Krempf M, Ikeda Y, Eagle KA, Elisaf M, Bhatt DL, Steg PG; REACH Registry Investigators.

Eur Heart J. 2015 Oct 21;36(40):2716-28. doi: 10.1093/eurheartj/ehv347. Epub 2015 Aug 4.

PMID:
26242715
37.

Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic Patients.

Croyal M, Ouguerram K, Passard M, Ferchaud-Roucher V, Chétiveaux M, Billon-Crossouard S, de Gouville AC, Lambert G, Krempf M, Nobécourt E.

Arterioscler Thromb Vasc Biol. 2015 Sep;35(9):2042-7. doi: 10.1161/ATVBAHA.115.305835. Epub 2015 Jul 9.

PMID:
26160958
38.

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group.

N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892.

39.

Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey.

Krempf M, Simpson RJ Jr, Ramey DR, Brudi P, Giezek H, Tomassini JE, Lee R, Farnier M.

Lipids Health Dis. 2015 May 19;14:45. doi: 10.1186/s12944-015-0037-y.

40.

[Does a slight overweight increase life expectancy?].

Krempf M.

Rev Prat. 2015 Jan;65(1):10-1. French. No abstract available.

PMID:
25842416
41.
42.

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; ODYSSEY LONG TERM Investigators.

N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15.

43.

Laparoscopic Gastric Banding in Obese Patients with Sleep Apnea: A 3-Year Controlled Study and Follow-up After 10 Years.

Feigel-Guiller B, Drui D, Dimet J, Zair Y, Le Bras M, Fuertes-Zamorano N, Cariou B, Letessier E, Nobécourt-Dupuy E, Krempf M.

Obes Surg. 2015 Oct;25(10):1886-92. doi: 10.1007/s11695-015-1627-5.

PMID:
25702144
44.

A Long-Term Model of the Glucose-Insulin Dynamics of Type 1 Diabetes.

Magdelaine N, Chaillous L, Guilhem I, Poirier JY, Krempf M, Moog CH, Le Carpentier E.

IEEE Trans Biomed Eng. 2015 Jun;62(6):1546-52. doi: 10.1109/TBME.2015.2394239. Epub 2015 Jan 20.

PMID:
25615904
45.

Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.

Kastelein JJ, Robinson JG, Farnier M, Krempf M, Langslet G, Lorenzato C, Gipe DA, Baccara-Dinet MT.

Cardiovasc Drugs Ther. 2014 Jun;28(3):281-9. doi: 10.1007/s10557-014-6523-z.

46.

Nicotinic acid effects on insulin sensitivity and hepatic lipid metabolism: an in vivo to in vitro study.

Blond E, Rieusset J, Alligier M, Lambert-Porcheron S, Bendridi N, Gabert L, Chetiveaux M, Debard C, Chauvin MA, Normand S, Roth H, de Gouville AC, Krempf M, Vidal H, Goudable J, Laville M; “Niacin” Study Group.

Horm Metab Res. 2014 Jun;46(6):390-6. doi: 10.1055/s-0034-1372600. Epub 2014 May 7.

PMID:
24806747
47.

Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: can we do better? Analysis of results obtained during the past two decades in 1669 French subjects.

Béliard S, Carreau V, Carrié A, Giral P, Duchêne E, Farnier M, Ferrières J, Fredenrich A, Krempf M, Luc G, Moulin P, Bruckert E.

Atherosclerosis. 2014 May;234(1):136-41. doi: 10.1016/j.atherosclerosis.2014.02.021. Epub 2014 Mar 3.

PMID:
24637413
48.

Residual macrovascular risk in 2013: what have we learned?

Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, Barter P, Betteridge J, Bruckert E, Cuevas A, Farnier M, Ferrannini E, Fioretto P, Genest J, Ginsberg HN, Gotto AM Jr, Hu D, Kadowaki T, Kodama T, Krempf M, Matsuzawa Y, Núñez-Cortés JM, Monfil CC, Ogawa H, Plutzky J, Rader DJ, Sadikot S, Santos RD, Shlyakhto E, Sritara P, Sy R, Tall A, Tan CE, Tokgözoğlu L, Toth PP, Valensi P, Wanner C, Zambon A, Zhu J, Zimmet P; Residual Risk Reduction Initiative (R3i).

Cardiovasc Diabetol. 2014 Jan 24;13:26. doi: 10.1186/1475-2840-13-26. Review.

49.

Acebutolol and alprenolol metabolism predictions: comparative study of electrochemical and cytochrome P450-catalyzed reactions using liquid chromatography coupled to high-resolution mass spectrometry.

Bussy U, Delaforge M, El-Bekkali C, Ferchaud-Roucher V, Krempf M, Tea I, Galland N, Jacquemin D, Boujtita M.

Anal Bioanal Chem. 2013 Jul;405(18):6077-85. doi: 10.1007/s00216-013-7050-7. Epub 2013 May 23.

PMID:
23700103
50.

In situ NMR spectroelectrochemistry for the structure elucidation of unstable intermediate metabolites.

Bussy U, Giraudeau P, Silvestre V, Jaunet-Lahary T, Ferchaud-Roucher V, Krempf M, Akoka S, Tea I, Boujtita M.

Anal Bioanal Chem. 2013 Jul;405(17):5817-24. doi: 10.1007/s00216-013-6977-z. Epub 2013 May 15.

PMID:
23673569

Supplemental Content

Loading ...
Support Center